02:57 PM EDT, 03/25/2025 (MT Newswires) -- Mural Oncology ( MURA ) said Tuesday it will stop the development of nemvaleukin alfa for platinum-resistant ovarian cancer as it believes a phase 3 trial of the drug combined with Merck's (MRK) Keytruda is "highly unlikely to achieve success" at the final analysis.

Shares of Mural slumped 59% following an increase in intraday trading volume to over 3.52 million from a daily average of about 156,000.

Cassava Sciences ( SAVA ) said that topline results from its phase 3 REFOCUS-ALZ study of simufilam showed no treatment benefit for patients with mild-to-moderate Alzheimer's disease.

The biotech company said the results did not meet the co-primary, secondary, and exploratory biomarker endpoints.

Shares sank 33%, with intraday trading volume rising to over 13.8 million versus a daily average of about 1.96 million.

Price: 1.53, Change: -2.30, Percent Change: -60.05